Asthma treatment drug candidate GUR-501 is a new innovative molecule with FIRST-IN-CLASS potential. It acts simultaneously on 3 new targets that are ЕР2 and EP4 prostanoid receptors and soluble guanylate cyclase.
• GUR-501 may be the only effective medicine for patients with a long history of asthma who have developed a tolerance to the existing bronchodilators. Existing drugs DO NOT HELP for such patients
• No tachycardia and muscular tremor compared with existing asthma treatment drugs (β2-agonists such as alupent, ventolin, salbutamol, berotec and M-cholinoblockers such as atropine and its analogs)